Navigation Links
Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/6/2008

cates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the enrollment, timing, execution and completion of clinical trials of its product candidates, the timing of an NDA submission for Contrave, the potential to obtain regulatory approval for, and effectively treat the specified disorders with its product candidates, and the potential issuance of patents and the scope and duration of protection of issued patents relating to the Company's product candidates. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the progress and timing of the Company's clinical trials; the potential that earlier clinical trials may not be predictive of future results; the ability for its product candidates to receive regulatory approval on a timely basis or at all; the potential for adverse safety findings relating to its product candidates to delay or prevent regulatory approval or commercialization, or result in product liability claims; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
5. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
6. CV Therapeutics Reports 2008 Third Quarter Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
9. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
10. Nile Therapeutics to Present at Two Upcoming Investor Conferences
11. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, ... distribution agreement with VWR to distribute TECTA™ B16, ... than 160 years of experience, VWR, a leading ... and production facilities, has cultivated a value proposition ... to enable science. Endetec’s TECTA™ B16, combines ...
(Date:5/20/2015)... 2015 This year has been one ... US Patented Pearl’s Premium Ultra Low Maintenance Lawn ... country that are coming out of record bad weather. ... of major global concerns related to water, health, and ... the alternative to the standard, water-wasting, chemical-treated standard lawn. ...
(Date:5/20/2015)... , May 20, 2015  Health eCareers, ... short-staffed healthcare organizations with job seekers looking for ... , a new mobile and online tool dedicated ... healthcare industry. SHIFT enables employers to ... tenens, travel nursing, per diem and other temporary ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... 2011 Pacific Shore Holdings, Inc. (previously Green Shores, Inc.), ... from the Financial Industry Regulatory Authority ("FINRA") for the change ... about the symbol change, as it takes us one step ... Markets. "Once we enter the Public Marketplace, we believe that ...
... IPSWICH, Mass., Feb. 14, 2011 New England Biolabs has ... ™ and One Taq Hot Start DNA Polymerases. Optimized ... DNA Polymerases, these new products offer robust amplification across a ... The 3´–5´ exonuclease activity of Deep Vent increases the fidelity ...
... Technology Catalysts International (TCI), leading global consultants to the ... in drug delivery have identified parenteral depots as key ... a different pathway for new drug development, and potential ... a crowded pharmaceutical field. In general, biopharmaceuticals ...
Cached Biology Technology:Pacific Shore Holdings, Inc. Receives Symbol Change Approval From FINRA 2New England Biolabs Introduces OneTaq™ DNA Polymerase, a Robust Solution for Routine and Difficult PCR 2Parenteral Depots Offer $8 Billion of Reformulation Opportunities and a Strong Competitive Edge in Crowded Pharmaceutical Space 2
(Date:4/20/2015)... DUBAI , April 20, 2015 ... soars   Glenbeigh Records Management (GRM), ... contract with Dubai Islamic Bank. Having built up an impressive ... is now a leading player within the records management sector ... company expects to double is GCC staffbase and employ a ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... Synaptics,(Nasdaq: SYNA ), a leading developer ... entertainment devices, today reported,financial results for the first ... reflect the expensing of non-cash share-based,compensation for all ... quarter of fiscal 2009 was $115.9 million, an,increase ...
... induce "synesthetic" experiences where one sense triggers the ... according to a new study in the journal ... for Psychological Society. The findings suggests that ... necessarily have extra connections in their brain; rather, their ...
... The Office of Dietary Supplements (ODS) at the National ... ninth issue of the Annual Bibliography of Significant Advances ... 2007 Bibliography include research supported by government, industry, and ... research covers a wide array of laboratory, human studies, ...
Cached Biology News:Synaptics Reports Record Results for First Quarter of Fiscal 2009 2Synaptics Reports Record Results for First Quarter of Fiscal 2009 3Synaptics Reports Record Results for First Quarter of Fiscal 2009 4Synaptics Reports Record Results for First Quarter of Fiscal 2009 5Synaptics Reports Record Results for First Quarter of Fiscal 2009 6Synaptics Reports Record Results for First Quarter of Fiscal 2009 7Synaptics Reports Record Results for First Quarter of Fiscal 2009 8Ben-Gurion University of the Negev researchers help find that hypnosis can induce synesthesia 2Annual Bibliography of Significant Advances in Dietary Supplement Research 2007 2
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
Bag-1 (K-20)...
IC50: 35 ng/ml · Limit of detection: 8 ng/ml...
... PGE2-d4 contains 4 deuterium atoms at ... It is intended for use as an ... E2 (PGE2) by GC- or LC-mass spectrometry. ... products of arachidonic acid and one of ...
Biology Products: